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Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool
Abstract: Aims: Methylation profiling (MP) is increas-
ingly incorporated in the diagnostic process of central
nervous system (CNS) tumours at our centres in The
Netherlands and Scandinavia. We aimed to identify the
benefits and challenges of MP as a support tool for CNS
tumour diagnostics. Methods: About 502 CNS tumour
samples were analysed using (850 k) MP. Profiles were
matched with the DKFZ/Heidelberg CNS Tumour Classi-
fier. For each case, the final pathological diagnosis was
compared to the diagnosis before MP. Results: In 54.4%
(273/502) of all analysed cases, the suggested methyla-
tion class (calibrated score ≥0.9) corresponded with the
initial pathological diagnosis. The diagnosis of 24.5% of
these cases (67/273) was more refined after incorpora-
tion of the MP result. In 9.8% of cases (49/502), the MP
result led to a new diagnosis, resulting in an altered
WHO grade in 71.4% of these cases (35/49). In 1% of
cases (5/502), the suggested class based on MP was ini-
tially disregarded/interpreted as misleading, but in retro-
spect, the MP result predicted the right diagnosis for
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three of these cases. In six cases, the suggested class was
interpreted as ‘discrepant but noncontributory’. The
remaining 33.7% of cases (169/502) had a calibrated
score <0.9, including 7.8% (39/502) for which no class
indication was given at all (calibrated score <0.3).
Conclusions: MP is a powerful tool to confirm and fine-
tune the pathological diagnosis of CNS tumours, and to
avoid misdiagnoses. However, it is crucial to interpret
the results in the context of clinical, radiological,
histopathological and other molecular information.
Keywords: central nervous system tumours, diagnostics, methylation profiling
Introduction
Diagnostics of benign to highly malignant central ner-
vous system (CNS) tumours is often complex. Some
tumours can be treated by surgery alone, whereas
others require multimodal treatment and the use of
diagnostic, prognostic and predictive biomarkers. Based
on histology, there is significant interobserver variation
in the diagnostics of particular CNS tumours [1].
Molecular analyses can help to reduce this interob-
server variation, especially now that there is increasing
knowledge about the characteristic molecular features
of many CNS tumour entities [2].
Mapping of epigenetic alterations in CNS tumours
has recently been shown to offer promising perspec-
tives. The diagnostic potential of DNA methylation pro-
filing (MP) by assessing the methylation status of
850,000 CpG sites across the entire human genome
has been explored by the German Cancer Research
Centre (DKFZ) and Heidelberg University [3,4,5]. They
have shown that methylation profiles of CNS tumours
share common features and that these profiles differ
between (histological) tumour entities. Hereby, they
conceived the concept of brain tumour DNA ‘finger-
printing’ by MP for CNS tumour classification. A DNA
methylation-based classifier tool is publicly available for
CNS tumour classification through a webpage
(www.molecularneuropathology.org, henceforth
referred to as ‘the Classifier’). Methylation profiles can
be uploaded to the Classifier and matched to a database
containing a reference cohort, initially of 2801 samples
covering 82 CNS tumour classes and nine control tis-
sue classes, which has been updated with many more
samples ever since [5]. The automated analysis results
in a calibrated score, representing the degree of match
between the methylation profile of the tumour of inter-
est and predefined methylation classes.
Recent studies using the Classifier have shown
that most WHO CNS tumour entities can be precisely
identified [6,7]. Especially for paediatric tumours, the
approach is promising. Namely, medulloblastomas,
which often have low mutation rates and absence of
frequently recurring hotspot mutations, can be
separated into several subgroups that are clinically
important [8]. Furthermore, DNA MP of ependymo-
mas has distinguished nine distinct subgroups [9]
with one subgroup, ependymoma, RELA fusion-
positive, already recognized as a separate entity in
the updated WHO 2016 classification. In fact, groups
of ependymomas categorized by methylation profiles
are clinically more homogenous than grouping based
on histology using WHO classification and grading
[9].
The copy-number variation (CNV) profile, obtained
along with the Classifier score, provides additional
information of high value in specific differential diag-
nostics settings [6]. The diagnostic relevance of CNVs is
emphasized, for example, in the cIMPACT-NOW update
3, introducing the combined gain of complete chromo-
some (Chr) 7 and loss of complete Chr 10 as a diagnos-
tic criterion for a diagnosis of ‘molecular
glioblastoma’[10]. Additionally, the DNA methylation-
based Classifier tool gives information on the methyla-
tion status of the MGMT promoter: a variable that is
relevant for therapy and prognosis in patients with
glioblastoma [11].
The aim of this study was to assess the diagnostic
impact of DNA methylation-based classification in
CNS tumour diagnostics and to discuss both benefits
and pitfalls encountered during the implementation of
the tool at our respective centres. Monitoring this is,
from our perspective, an important part of
introducing new methods for (CNS) tumour
diagnostics.
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Materials and methods
DNA methylation-based tumour classification has been
increasingly incorporated in the diagnostic process at
our centres. In The Netherlands (NL), MP is performed
at the University Medical Centre Utrecht (UMCU) for
(challenging) in-hospital CNS tumour cases, for all CNS
tumours of paediatric patients from the Princess
Maxima Centre for Paediatric Oncology (PMC) and for
referred cases with a challenging diagnosis from other
Dutch centres. In Odense, Denmark (DK), MP was per-
formed on selected, often challenging in-hospital CNS
tumour cases (including some paediatric cases), as well
as referred cases from other centres in Denmark, Swe-
den, Norway and Finland.
Patients
About 502 CNS tumour samples analysed between Octo-
ber 2016 and April 2018 were included, of which 279
samples were from adults and 223 from children. The
following exclusion criteria were applied: diagnosis other
than primary CNS tumour, no suggested histological
diagnosis before DNA MP, missing clinical information,
cases analysed in research setting and duplicate cases
(e.g. repeated tests on the same material or if more than
one sample from a tumour was available, only the result
with the best calibrated score was kept for analysis). The
total number of unique patients was 480: 20 of these
patients were included with two samples and one patient
with three samples. In case of samples from one patient
from different locations/components (n = 3) or different
points in time (e.g. initial and recurrent disease, n = 18),
both entries were included for statistical analysis.
Reasons to perform MP were categorized in four
major groups: (i) ‘Routine/gain experience with tool’
(e.g. all paediatric cases from the PMC were routinely
subjected to MP); (ii) ‘Challenging diagnosis’ (including
cases with unusual/nonspecific histology or unclear
molecular findings); (iii) ‘Subclassification’ (especially in
case of ependymomas or medulloblastomas); (iv) ‘Revi-
sion/re-evaluation’. This last category included a mix
of cases with an unexpected clinical course (e.g. unu-
sual recurrent disease or long-term survival, metastasis
outside of CNS), unresolved tumour cases and cases
analysed specifically to find possible therapeutic
options. A list of the (first differential) diagnosis of all
analysed tumours is given in Table S1.
Sample preparation
Most (n = 448) samples were isolated from formalin-
fixed paraffin-embedded (FFPE) tissue and 17 from
fresh-frozen (FF) tissue. In 36 cases, DNA was isolated
at different hospitals (generally also from FFPE tissue)
and sent to our centres for MP. One sample was forma-
lin-fixed agar-embedded. Whole unstained slides were
used or areas with the highest tumour cell content
were macrodissected for DNA isolation. Estimated
tumour cell content was highly variable (Figure 1B).
DNA was isolated using NorDiag Arrow using the Dia-
Sorin DNA extraction kit (NL) or GeneRead DNA FFPE
Kit (Qiagen, Hilden, Germany) (DK) according to the
respective manufacturer’s instructions. DNA concentra-
tion was measured using the Qubit 2.0 fluorometer
and ranged from 0.1 to 875.5 ng/ll. Per sample, we
aimed to use 500 ng (DK) or 200 ng (NL) of DNA.
Bisulphite conversion was performed with EZ DNA
MethylationTM Kit (Zymo Research, Irvine, CA, USA).
Methylation profile analysis
All methylation data were generated using the Illu-
mina MethylationEPIC (850 k) BeadChip platform as
described by Capper et al. (2018) [5]. All FF samples were
processed along with FFPE samples on the same EPIC
chip. The profiles, contained in paired IDAT files, were
matched with the Classifier using the current version at
the time of original upload (mostly v11b2, v11b4 since
January 2018; www.molecularneuropathology.org).
The Classifier will provide, if possible, a match to a
methylation ‘family’ and if applicable to a ‘subclass’
within that family, each accompanied by a calibrated
score (ranging from 0.3 to 0.99). This score gives an
indication of the degree of match between the methyla-
tion profile of the sample and the methylation profiles of
samples in the reference database. The Classifier is
unable to assign a methylation class when the calibrated
score falls <0.3 and no exact calibrated score is given
between 0.0 and 0.3. Samples were not generally reclas-
sified after the Classifier version update during the prepa-
ration of this manuscript, except for 23 cases from NL for
which the calibrated score for the subclass was missing
due to temporary problems with the online access to the
Classifier tool at the time of original upload. Reclassifica-
tion of these 23 cases did not lead to significant changes
in calibrated scores or assigned methylation classes.
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Data collection and statistical analysis
The variables that were collected in the database for all
cases are presented in Table 1. Tumours were graded
according to the WHO Classification of Tumours of the
CNS that was valid at the time of first diagnosis (mostly
4th revised edition of 2016). This study includes 84
tumour samples dating from 2007 to 2015, 11 tumour
samples dating from 2002 to 2006 and one tumour
sample from 1994. For these samples, the initial diag-
nosis was based on the WHO classifications from 2007,
2000 and 1993 respectively. Integration of the MP
result into the final diagnosis, and (if applicable) recon-
sideration of the histopathology in case of a discrepant
methylation class, was done by the pathologist request-
ing the test (hereafter referred to as the ‘original
pathologist’). Next, all tumours were categorized into
eight groups comparable to the categorization used by
Figure 1. (A) Effect of estimated tumour cell percentage on calibrated score: Scatter plot of average tumour cell percentage (x-axis)
versus calibrated score for MP class family (Y-axis). Cases from NL: green circles; cases from Scandinavia: red diamonds; purple crosses:
mean. Horizontal lines: blue solid - threshold of calibrated score ≥0.9; blue dashed -possible alternative threshold for calibrated score at
≥0.84 as suggested by [6] Cases with ‘no match <0.3’ (no calibrated score provided) were given the value 0 to be able to visualize them
in this plot. The mean calibrated score of samples for which no tumour cell percentage was available is plotted at the bottom of the x-
axis, marked with ‘N/A’. NB. Symbols are often superimposed; labels at the top show the number of plotted cases. (B) Distribution of
cases by calibrated scores for methylation class family: bar chart showing frequency of cases (Y-axis) with specified calibrated score (X-
axis) for 468 cases with MP result. Valid matches with calibrated score ≥0.9 presented in green; no match cases with calibrated scores
0.84-<0.9 in orange, remaining no match cases with calibrated scores 0.31-<0.84 in blue. Data on no match cases with scores < 0.3 are
not shown.
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Capper et al. [5]. The ‘no match’ cases were subdivided
into three groups based on the calibrated score for the
methylation class family: <0.3; 0.3 to <0.7 and 0.7 to
<0.9. Detailed information on these categories is given
in Supplement 1. For each case with a changed diagno-
sis, the consequence for the WHO grade (upgraded,
downgraded or unchanged) was evaluated.
Statistical analyses (mainly descriptive such as fre-
quencies, mean and standard deviation, t-tests, Fisher’s




Of 502 included samples (Table 2), 223 were paediatric
(mean age 8.7 years) and 279 were from adult patients
(mean age 50.9 years); 55.6% (279/502) samples were
from males, and 44.4% (223/502) samples from female
patients. Most samples were obtained at initial presen-
tation of the disease (88.2%, 443/502), while fewer
were from recurrent disease (11.6%, 58/502) or a
metastasis (0.2%, 1/502). The main reason to perform
MP was ‘routine/gain experience with tool’ (67.3%,
338/502). The other cases were analysed because of a
challenging (differential) diagnosis (17.7%, 89/502),
specifically to be able to subclassify the tumour (8.6%,
43/502, of which 40 were paediatric) or as a part of
revision/re-evaluation during the course of the disease
(6.4%, 32/502).
Assay performance
Using a calibrated score with a cut-off of ≥0.9 (as sug-
gested by Capper et al. [5]), the Classifier was able to
find a match with a methylation class family/subclass
in 66.3% of cases (333/502 analysed samples) (Fig-
ure 1A, and subclasses in Figure S1). When using the
cut-off of ≥0.84 (possible alternative cut-off value, as
more recently suggested by Capper et al. [6]), this per-
centage rises to 70.9% (356/502) (Figure S2). Despite
the slightly different approach in DNA extraction and
added DNA amount in NL and DK (max. 200 and 500
respectively), there was no significant difference in the
percentage of cases for which a match (cut-off ≥0.9)
was obtained: 68.4% (216/316) for NL and 62.4%
(116/186) for DK (P = 0.173). A match was obtained
in 71.7% (160/223) of paediatric cases (cut-off ≥0.9)
and in 61.6% of adult cases (172/279). Assay perfor-
mance was similar for cases at initial presentation vs.
cases of recurrent disease, with a match made at a
Table 1. Collected variables per case for database
Collected variables per case
Tissue type
Original pathological diagnosis prior to MP
Differential diagnosis prior to MP
WHO grade of (first differential) diagnosis prior to MP
Reason to perform methylation profiling
Tumour location




DNA amount added to assay (ng/45 µl)
Year of tissue block
Year of array analysis
Highest scoring methylation class or family
Highest scoring methylation subclass
Calibrated scores for family and subclass
Final pathological diagnosis post MP
WHO grade of the final pathological diagnosis
Table 2. Cohort characteristics of 502 cases included for analysis





Freq % Freq % Freq %
Region
Scandinavia 148 53.0 38 17.0 186 37.1
Netherlands 131 47.0 185 83.0 316 62.9
Gender
M 150 53.8 129 57.8 279 55.6
F 129 46.2 94 42.2 223 44.4
Disease stage
Initial 241 86.4 202 90.6 443 88.2
Recurrent 37 13.3 21 9.4 58 11.6
Metastasis 1 0.4 0 0 1 0.2




194 69.5 144 64.6 338 67.3
Challenging
diagnosis
60 21.5 29 13.0 89 17.7
Subclassification 3 1.1 40 17.9 43 8.6
Revision/re-
evaluation
22 7.9 10 4.5 32 6.4
Mean SD Mean SD
Age 50.83 16.917 8.69 5.545
Freq, frequency; SD, standard deviation.
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calibrated score of ≥0.9 in 66.1% (293/443) vs. 65.5%
(39/58) of cases, respectively, and in 70.9% (314/443)
vs. 70.7% (41/58) of cases, respectively, when using
the cut-off of ≥0.84. The case presenting as metastatic
disease of a primary CNS tumour (n = 1) was excluded
from this analysis. For the 18 patients from whom both
material from initial and recurrent disease were anal-
ysed, the effect of the MP result was various, including,
for example, no match (<0.9) for both samples (six
patients); establishing new diagnosis (≥0.9) for one (five
patients) or both samples (one patient) or confirmation
(and refinement) of diagnosis (≥0.9) for both samples
(six patients). Out of nine patients with a calibrated
score ≥0.9 for both samples, five patients had identical
final and initial diagnoses. In one case, there was indi-
cation of disease progression with diffuse astrocytoma,
IDH-mutant (grade II) diagnosed on the initial sample
and glioblastoma, IDH-mutant diagnosed on the recur-
rent sample. In another case, glioblastoma IDH-wild-
type, subtype midline was diagnosed on the recurrent
sample, after an initial diagnosis of low-grade diffuse
astrocytoma/glioma, IDH-wildtype (grade II). Finally, in
one case, the MP results and CNV profiles of initial (final
diagnosis pilocytic astrocytoma) and ‘recurrent’ sample
(final diagnosis glioblastoma, IDH-wildtype) contributed
to identifying the latter as a second primary tumour.
Tissue block age was computed by subtracting the
year the tissue block was made from the year of MP
analysis. Tissue block age ranged from 0 to 23 years,
with a mean of 1.22 years (SD 2.82). For cases, for
which a match to a methylation class could be made
at cut-off ≥0.9, tissue age ranged from 0 to 13 years,
with a mean of 1.08 years (SD 2.45) and for no match
cases (cut-off <0.9), the tissue age ranged from 0 to 23
with a mean of 1.47 years (SD 3.43) (P = 0.147). For
all cases combined (n = 502) (including cases with cali-
brated scores <0.3 given the value ‘0’), the determina-
tion coefficient R2 was 0.012, showing that 1.2% of
the variance in calibrated score for the class family can
be explained by tissue block age, with a P-value of
0.015 (Figure S3). Excluding the cases that did not
reach the threshold of 0.3 for the calibrated score
(n = 463), the R2 was 0.006 (P = 0.104).
In our series, the use of FF (although few in number)
or FFPE material did not significantly affect the assay
performance. A match with a calibrated score of ≥0.9
was obtained in 64.7% (11/17) of FF cases and in
66.5% of FFPE cases (298/448) (P = 0.531). The cases
in which DNA was isolated elsewhere (n = 36) and the
case for which the tissue was embedded in agar (n = 1)
were left out of this analysis.
In 7.8% of cases (39/502), the calibrated score of
the Classifier was too low (<0.3) and no match to a
methylation class was found. There was no clear tech-
nical explanation why the performance of the assay
was insufficient for these cases. For example, tumour
cell percentage ranged from 10 to 100% (mean 62.6;
SD 23.3, Figure 1B). Also, DNA concentration (range
0.2–49 ng/ll, mean 12 ng/ll, SD 12.9 ng/ll) and
total amount of DNA added (range 11–500 ng, mean
193.6 ng, SD 114 ng) were not particularly low for
these cases. Similarly, the age of the tissue blocks used
for analysis did not strikingly differ from those for
which a match was made at a calibrated score >0.3.
For these cases, tissue block age ranged from 0 to
16 years (mean 2.03 years; SD 3.67 years). The diag-
noses prior to MP were also not particularly ‘rare’
(listed in Table S2) and there was no indication that
germline mutations could be responsible for the low
score in these cases.
Impact of suggested methylation class on diagnosis
Confirmation of diagnosis/confirmation and refinement
(≥0.9) In 54.4% of cases (273/502), the outcome of
MP matched the initial histological diagnosis: in 41.0%
(206/502) of the analysed cases, the suggested
methylation class corresponded exactly with the initial
pathological diagnosis (based on histology with or
without molecular analysis) and the diagnosis of 13.3%
of cases (67/502) was more refined after incorporation
of the MP result (Figure 2). For example, cases with the
histological diagnosis medulloblastoma could be
assigned a subgroup (WNT-activated, SHH-activated and
non-WNT/non-SHH) (n = 24). For ependymomas,
particular groups such as ependymoma with RELA
fusion (n = 2) or myxopapillary ependymoma (n = 2)
could be specified. There were a few cases in which the
diagnosis of myxopapillary ependymoma was suggested
by the Classifier, while (according to the reporting
pathologist) histologically no myxopapillary features
could be identified upon revision (n = 4). These
ependymoma cases were categorized as ‘confirmation of
diagnosis (≥0.9)’. Of note, according to the DKFZ/
Heidelberg methylation class description (www.molecula
rneuropathology.org), this class encompasses both
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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ependymomas with myxopapillary features and to a
lesser extent ependymomas with classical or rarely
tanycytic histology. The classifier effect ‘confirmation
and refinement’ was more common in the paediatric
part of the cohort. This can be explained by the much
larger proportion of medulloblastomas and
ependymomas in the paediatric cohort, that is, tumours
for which subclassification is clinically relevant and
nowadays warranted [8,9].
Establishment of new diagnosis (≥0.9) In 9.8% of cases
(49/502), the MP result led to a new integrated
diagnosis to that of the original pathologist
(Figure 3A). Of the cases in which a new diagnosis was
established after MP, 11 cases had a lower WHO grade,
24 cases had a higher WHO grade and in 14 cases, the
WHO grade was unchanged (Figure 3B). A change in
WHO grade occurred in challenging cases (n = 7),
cases analysed during revision/re-evaluation (n = 7)
and in cases analysed as a part of routine diagnostic
work-up (n = 20). The effects of the Classifier result
were similar for the paediatric cases compared to the
adult cases. For example, a new diagnosis was
established in 8.5% of paediatric cases (19/223) vs.
11.1% of adult cases (31/279) (P = 0.451)
(Figure S4A,B).
‘Misleading/disregarded profile’ (≥0.9) In very few cases
with a calibrated score ≥0.9 (1%, 5/502), the
suggested class based on MP was not adopted by the
original pathologist, because the MP outcome did not
match the preferred histological diagnosis and/or was
Figure 2. Effect of methylation profiling on diagnosis signed out to the clinicians for 502 cases with a calibrated score ≥0.9: light orange
pie section represents all ‘no match’ cases combined. These are subdivided into calibrated scores <0.3; 0.3 to <0.7 and 0.7 to <0.9 in the
bar to the right of this pie section. Labels represent: n (%) of 502 cases total.
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considered not to fit the clinical or radiological context
(Table S3). An example of a case in this category is
described in detail under ‘Special illustrative cases’.
Importantly, thorough review of the follow-up of these
cases showed that in three of these cases, the MP result
actually predicted clinical behaviour better than the
diagnosis signed out by the original pathologist.
Discrepant but noncontributory (≥0.9) Six cases were
categorized as ‘discrepant but noncontributory (≥0.9)’
(Table S4). Five of these cases were classified as control
tissue, which did not match the presence of tumour cells
upon histology. Interestingly, three of these cases had
relatively high estimated tumour cell contents (60–80%)
and adequate quantities of DNA were available in four
cases (200 ng). It is unclear why these cases failed to
classify into a specific tumour entity. The sixth case
concerns a tumour initially diagnosed as ganglioglioma
with a differential diagnosis of pleomorphic
xanthoastrocytoma (PXA), which was classified as PXA.
The Classifier description for this class states that
‘tumours in this class may also show a ganglion cell-like
differentiation and may then histologically appear as
anaplastic ganglioglioma’. The reporting pathologist
interpreted this result as ‘not excluding the diagnosis of
ganglioglioma’ and the final report stated a preferred
diagnosis of ganglioglioma. Thus, the MP result was not
strictly misleading but was not completely followed
either, which is why the case was categorized as
discrepant but noncontributory.
No match cases (0.3 to <0.7 and 0.7 to <0.9) Twenty-
six per cent of all cases (130/502) were assigned to a
methylation class with calibrated scores between 0.3
Figure 3. New diagnoses after methylation profiling: (A) Overview of initial (left) and new diagnoses after MP (right) in cases classified
as ‘Establishing new better diagnosis (≥0.9)’ (n = 49). (B) WHO grade effects in cases with establishment of new diagnosis: Difference
between WHO grade original diagnosis and final diagnosis for cases categorized as ‘Establishment of new better diagnosis (≥0.9)’
(n = 49), subdivided by reasons to perform MP. Green shades: downgraded, blue shades: unchanged, red shades: upgraded.
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and <0.7 (n = 70) or 0.7 and <0.9 (n = 60). For some
cases, the methylation class and accompanying CNV
plot could still be helpful for the diagnosis: for example,
establishing a new diagnosis in 8.3% (5/60) of cases
with calibrated score of 0.7 to <0.9 and in 7.1% (5/
70) of cases with calibrated score of 0.3 to <0.7
(Figure 4A,B). Also, for a large proportion of cases, the
histological diagnosis could be confirmed or confirmed
and refined: 51.7% (31/60) and 5% (3/60) of cases
with calibrated score 0.7 to <0.9, respectively, and
35.7% (25/70) and 10% (7/70) of cases with
calibrated score 0.3 to <0.7 respectively. As expected,
the percentage of cases for which the methylation class
would have been potentially misleading was high in
these groups: 20.0% (12/60) of cases with calibrated
score 0.7 to <0.9 and 31.4% (22/70) of cases with
calibrated score 0.3 to <0.7.
Special illustrative cases
Case 1- ‘Misleading/disregarded profile’ In this 15-year-
old girl who presented with progressive headache,
nausea, blurred vision and diplopia, imaging revealed a
tumour in the pineal region (Figure 5A). The differential
diagnosis at that time included germinoma, astrocytoma
and pineocytoma/pineoblastoma. Histopathological
evaluation of the biopsies revealed a small blue round
cell tumour with brisk mitotic activity and a few
dispersed Homer Wright-like rosettes (Figure 5B).
Immunohistochemically, the tumour cells were positive
for synaptophysin and showed a MIB-1 labelling index of
60%. Combined with the information on its location, the
tumour was histologically diagnosed as pineoblastoma.
Surprisingly, MP suggested ‘medulloblastoma, WNT’
with an almost perfect calibrated score (0.99), with loss/
monosomy of complete Chr 6 in the CNV plot
(Figure 5C). Additionally, next-generation sequencing
(NGS) revealed a CTNNB1 mutation (p.(Ser33Phe)). The
CNV plot generated with single-nucleotide
polymorphism (SNP) array analysis was identical to that
based on MP, and fluorescent in-situ hybridization
(FISH) and SNP data combined suggested polysomy with
(indeed) relative loss of Chr 6 (Figure S5). The
combination of CTNNB1 mutation and monosomy of
Chr 6 is typically found in WNT-activated
medulloblastomas. One may speculate that occasionally
otherwise prototypical medulloblastomas can occur in
extraordinary locations such as the pineal region, for
example, because of ectopic location of progenitor cells
that usually are confined to the posterior fossa. For the
time being, however, because of the tumour location
(and after ruling out additional tumours in the posterior
fossa), the diagnosis suggested by MP analysis was
considered to be unfitting and the final integrated
diagnosis was ‘pineoblastoma (WNT-activated), WHO
grade IV’. It is presently unknown if WNT activation has
the same favourable prognostic meaning in
pineoblastomas as in medulloblastomas.
Case 2 - Establishment of new diagnosis A 42-year-old
woman presented with a tumour in the cerebellum
close to the brainstem (Figure 5D). The histology (5-
mm biopsy) showed a tumour with low cellularity
composed of small monomorphic tumour cells focally
arranged in perivascular pseudorosettes (Figure 5E).
Immunohistochemistry showed positive staining for
GFAP, Olig2 and ATRX and a low MIB-1 labelling
index (<1%). IDH1-R132H staining was negative.
Sequencing identified PIK3CA and NF1 mutations. The
findings indicated a low-grade glioma, possibly an
ependymoma, and irradiation was considered. A match
to the methylation class low-grade glioma, rosette-
forming glioneuronal tumour and a flat CNV plot was
obtained by MP (Figure 5F). Additional synaptophysin
immunostaining was performed and immunoreactivity
was found in the pericapillary area of perivascular
pseudorosettes as expected for this entity. This
diagnosis was also supported by the coexisting
mutations in PIK3CA and NF1, which is in line with
the recent study on rosette-forming glioneuronal
tumours by Sievers et al. [12].With a WHO grade I
diagnosis instead of a WHO grade II diagnosis, the
oncologists decided not to irradiate the tumour and
thereby to avoid potential radiation-related side effects.
Discussion
DNA methylation-based tumour classification of CNS
tumours was implemented in our clinical diagnostic
practices using the Classifier developed by Capper et al.
(2018). 502 CNS tumours were analysed for a variety
of reasons, for example, as a part of routine tumour
work-up, because of a challenging diagnosis, because it
was requested by an external lab or to learn about the
tool. A match to a specific methylation class with a cal-
ibrated score ≥0.9 was reached for 66.3% (333/502) of
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the tumour samples. Capper et al. reported a match to
a methylation class in 88% of the analysed tumours in
a clinical validation study with more than 1100 CNS
tumours [6]. Our results are more in line with the data
from a few of the five external centres, also reported by
Capper et al., which had implemented MP in a
Figure 4. (A) Effect of methylation profiling on final pathological diagnosis of 60 cases with calibrated score of 0.7 to <0.9 for the
methylation class family: N/A refers to unresolved cases. Labels represent: n (%) of 60 cases total. (B) Effect of methylation profiling on
final pathological diagnosis of 70 cases with calibrated score of 0.3 to <0.7 for the methylation class family: N/A refers to unresolved




Figure 5. Case 1. (A) MR image, T1-weighted after IV Gadolinium-based contrast administration: tumour in the pineal region of a 15-
year-old girl. (B) H&E stain 109. (C) MP CNV plot, showing loss of chromosome 6. Case 2. (D) MR image, T1-weighted after IV
Gadolinium showing a tumour in cerebellum with close relation to the cerebral aqueduct and brainstem. (E) H&E stains 109, arrows
indicating focal perivascular pseudorosettes. (F) CNV plot showing a flat baseline with no indication of chromosomal changes in this
tumour. Scale bars indicate (B) 100 lm; (E) 250 lm.
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clinicopathological setting. Combined, these centres
analysed 401 cases, and for the individual centres, the
percentage of match to a methylation class varied
between 58 and 95% (78% match at a calibrated score
of ≥0.9 for all five centres combined). Of note, the
results presented in this study are based on the analysis
of samples in a daily diagnostic setting, including, for
example, suboptimal biopsy material. Although the
majority of included cases were from our own neuro-
surgery departments, referred cases with challenging
diagnoses were also included, most likely creating a
slight bias towards more difficult cases. This possibly
resulted in a higher percentage of cases that were diffi-
cult to classify, although Karimi et al. (2019) reported
a clinically significant contribution of the MP result to
the final diagnosis in 84% of a cohort of 55 challeng-
ing cases [13]. It remains unclear in what setting the
cases analysed by the individual centres presented by
Capper et al. were selected, and this might explain the
better performance of the Classifier at some of these
centres.
A new diagnosis was established in 9.8% (49/502)
of the cases in favour of the diagnosis indicated by MP.
This was based on a match to a specific DNA methyla-
tion class with a calibrated score ≥0.9, sometimes in
combination with aberrations as seen in the CNV pro-
file generated based on MP and/or available immuno-
histochemical findings or NGS results. In comparison,
Capper et al. reclassified 12% of the cases (for individ-
ual centres, this varied between 6 and 25%). The IDH-
wildtype astrocytic gliomas, WHO grade II-III were
most frequently reclassified (28.6%, 14/49): most of
these as glioblastoma (n = 8). The fact that a number
of IDH-wildtype astrocytic gliomas, WHO grade II-III
were reclassified as glioblastoma is in accordance with
the new recommendations from cIMPACT-NOW update
3, which states that such tumours without prototypical
histological features of glioblastoma but with combined
gain of complete Chr 7 and loss of complete Chr 10
and/or a high copy amplification of EGFR and/or a
TERT promoter mutation should nowadays be consid-
ered as molecular glioblastoma, IDH-wildtype [10].
Thereby, the CNV profile that accompanies the Classi-
fier result can thus be very helpful in the diagnostic
process. Of note, further refinement of diagnoses can
now also be provided for meningiomas using the
Meningioma classifier [14] and for medulloblastomas
group 3/4 using the Medulloblastoma classifier [8].
We found that in 1% (5/502) of the cases, the result
of the MP was initially disregarded/considered mislead-
ing, and the diagnosis before MP was maintained by
the original pathologist (e.g. Case 1, Figure 5). How-
ever, thorough revision of these cases learned that the
MP result for three of these cases was actually right.
Since the start of the implementation of the Classifier
tool in our centres, new insights have emerged and
new molecular diagnostic criteria (e.g. c-IMPACT-NOW
update 3 [[10]) have been introduced in the field of
CNS tumour diagnostics. Based on current insight on
IDH-wildtype astrocytic tumours, WHO grade II-III, one
of the misleading cases (low-grade glioma, IDH-wild-
type) would not have been classified as misleading but
instead, the MP result would have confirmed the diag-
nosis of a diffuse astrocytic glioma, IDH-wildtype, with
molecular features of glioblastoma, WHO grade IV
(Table S3). In two of the other misleading cases
(anaplastic astrocytoma, IDH-wildtype and diffuse
astrocytoma, IDH-wildtype), later tumour recurrences
displayed the histological high-grade features that were
initially missing, primarily preventing the neuropathol-
ogists from following the MP result when evaluating
the primary tumour. Regarding the last misleading case
(rosette-forming glioneuronal tumour), later molecular
analyses did not support the histopathological diagnosis
given. In retrospect, these cases would have been cate-
gorized in the category ‘Establishment of new diagno-
sis’. Thus, these cases illustrate the significance of the
learning curve of those involved in the interpretation of
MP results and that categorization of cases in the pre-
defined categories is not ‘static’ but may change as
knowledge and experience expand.
The identification of cases that do not achieve a
match at a calibrated score of ≥0.9 (33.7%, 169/502
in this study) is important, as they contribute to the
ongoing improvement and refinement of the DNA
methylation-based Classifier tool. Investigation of
underlying molecular alterations and identification of
unifying features helps segregate these cases and may
help to define novel entities [15,16].
Among our 502 cases, 223 samples were from pae-
diatric patients. It has previously been suggested that
the performance of the Classifier is poorer for samples
from paediatric patients than for samples from adult
patients, because more rare tumours tend to occur in
the paediatric cohort [6]. This does not hold true for
our cohort (71.7% match made at ≥0.9). An
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explanation for this might be that most of the tumour
samples from paediatric cases in our series consisted of
tumour types that are well represented in the reference
cohort used for the development of the Classifier (e.g.
medulloblastoma, ependymoma and pilocytic astrocy-
toma). Similar to previously reported data by Pickles
et al. (2019) [17], MP results especially contributed to
(molecular) subtyping/refinement of the diagnosis for a
large portion of the paediatric cohort (39%, 93/223).
In addition to its role in routine diagnosis, MP may
also prove to be an invaluable tool in the identification
of new paediatric brain tumour classes [18].
We have looked at several technical parameters that
could influence the performance of the MP assay, such
as tumour cell percentage, sample fixation (FF/FFPE),
DNA concentration, DNA amount and age of the tissue
block. However, none of these parameters seemed to
have a clear effect on the likelihood that a match could
be made with a methylation class family/subclass. The
regression analysis between tissue block age and assay
performance revealed that the tissue block age had a
weak/negligible effect (1.2% variance, P = 0.012) on
the calibrated score for the class family. These results
indicate a very good assay performance even on old tis-
sue blocks (>5–10 years). However, our results may be
biased as the majority of samples included in our study
were less than 5 years old. Additional comparative
studies exclusively including old tissue blocks of differ-
ent age intervals are needed to get a better idea of any
tissue age-dependent effects on the assay performance.
The correlation between tumour cell percentage and
array performance was not straightforward. For the
cases with ‘no match <0.3’, tumour cell percentage
ranged from 10 to 100% and there were several cases
with good assay performance (that is, match made at
calibrated score ≥0.9) with low estimated tumour cell
percentage (as low as 15%). Of note, the estimation of
tumour cell percentage is notoriously imprecise [19].
Nonetheless, intuitively, it appears important to analyse
tumour DNA of vital tumour and to minimalize DNA
isolation from normal tissue as well as from necrotic
areas, as these might result in suboptimal or erroneous
classification (e.g. too low calibrated score or classifica-
tion as normal/control tissue). Therefore, in our routine
diagnostics, we aim to macrodissect vital tumour tissue
to obtain preferably >30% tumour cells.
Although the number of assays performed with FF
material was small, we did not observe a significant
difference in assay performance when using FF or FFPE
as input material with regard to the percentage of cases
for which a match was made with a good calibrated
score (FF: 64.7%; FFPE: 66.5%). It should be noted that
the recommended restore step was performed for all
FFPE samples. In addition, the DKFZ/Heidelberg Classi-
fier was built on MP data sets obtained from DNA iso-
lated from FFPE patient samples. However, because
DNA extracted from FF material is generally of higher
concentration and superior quality compared to what
can be obtained from FFPE material, the former may be
preferred (especially in cases where FFPE material is
very old).
In this study, the overall fraction of cases with a
match at a calibrated score ≥0.9 was comparable
between The Netherlands and Scandinavia, with 68%
and 62% match respectively. This suggests that MP is
a robust approach, withstanding slightly different
approaches in purification procedures and variation in
DNA amounts. The original instructions for the perfor-
mance of the EPIC array by Illumina state that the
assay requires an input of ≥250 ng of genomic DNA.
We did not attempt to define a lower cut-off of DNA
amount in this study, but in our experience, even sam-
ples with low DNA quantities of questionable quality
from ‘old’ material can be successfully classified. Yet, to
facilitate the interpretation of the MP results, four tech-
nical parameters deemed relevant for assay perfor-
mance are valuable to include in the pathology reports:
quantity of DNA input, estimated tumour cell percent-
age, quality of bisulphite conversion and percentage of
detected CpG sites.
We have not investigated the possible treatment con-
sequences of each case after DNA MP. Also, we do not
have clinical follow-up of all the cases that were
included, to allow consideration of clinical behaviour of
the tumour. It remains to be elucidated whether MP
results with a good calibrated score (≥0.9) might over-
rule the histopathological diagnosis, such as in cases
like the ‘ganglioglioma’ classified as pleomorphic xan-
thoastrocytoma as shown in Table S4. Furthermore, in
our experience, MP results with a calibrated score <0.9
can also be useful, though the percentage of ‘mislead-
ing profiles’ increased significantly the lower the cali-
brated score (2.2% when using ≥0.84 cut-off; 20% for
cases with calibrated score 0.7 to <0.9 and 32.4% for
cases with calibrated score 0.3 to <0.7). Further explo-
ration of the best cut-off value for the calibrated score
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
NAN 2020; 46: 478–492
Brain Tumour Diagnosis by Methylome Profiling 489
and how to interpret the data in cases with a (some-
what) lower score are warranted.
No specific data on the turn-around time have been
included in this study, as many cases were analysed ret-
rospectively. In addition, workflows have been optimized
and adjusted to the expected sample load since the start
of this study, making it difficult to provide exact data on
turn-around times. Now, 3 years after the introduction
of the tool, we have a turn-around time of a maximum
of 2 weeks (array processed once per week). Only in the
instance that analysis has to be repeated due to technical
problems (registered for 12 out of 502 cases in this data-
base, 2–3% of current cases) or if there are left over cases
but too few to fill an additional chip, this may be longer.
Our clinicians are aware of this workflow and know they
can anticipate the MP result about 2 weeks after MP
testing has been ordered.
To conclude, DNA MP is a very powerful tool to sup-
port the clinical diagnosis of CNS tumours, especially in
cases where morphological and genetic features are
inconclusive. The fact that the assay provides different
levels of information (tumour classification with family
and subclass, CNV’s and single gene promoter methyla-
tion status) makes it extra valuable. However, to avoid
misdiagnoses and to achieve therapeutic management
decisions, it is crucial to interpret the results of MP in
the context of clinical, radiological, histopathological
and other molecular information. For transparent inte-
gration of the results obtained with MP in the clinical
diagnostic process, we suggest to add these results to
‘layer 4’ of the integrated diagnostics approach as pro-
posed by the International Society of Neuropathology-
Haarlem consensus guidelines [[20] and more recently
by the International Collaboration on Cancer Reporting
(ICCR) guidelines as well ((http://www.iccr-cancer.org/
datasets/published-datasets/central-nervous-system).
This would facilitate continuous multidisciplinary eval-
uation of the molecular and epigenetic information and
adjustment of the interpretation as knowledge evolves.
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Supporting information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Fig S1.Distribution of cases by calibrated scores for
methylation subclass:Frequencies of calibrated score for
methylation subclass of 280 cases for which subclass
was specified.Cut-off value for the MP subclass was set
at ≥0.50 by Capper et al. (5).
Fig S2. Effect of methylation profiling on diagnosis for
502 cases with a calibrated score ≥0.84 (possible alter-
native cut-off value for calibrated score, suggested by
Capper et al.(6)): Categorization of the cases based on
the effect of methylation profiling on the diagnosis
signed out to the clinicians. Light orange pie section
represents all ‘no match’ cases combined. These are
subdivided in calibrated scores <0.3; 0.3-<0.7 and 0.7-
<0.84 in the bar to the right of this pie section. Labels
represent: n (%) of 502 cases total..
Fig S3. (A) Distribution of calibrated scores for methy-
lation class family by tissue block age of FFPE samples
(n=448): purple circles: values for individual samples
(some symbols superimposed); red crosses: mean cali-
brated for methylation class family. Horizontal lines -
blue solid: threshold of calibrated score ≥0.9; blue
dashed: possible alternative threshold for calibrated
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score at ≥0.84 as suggested by (6).Cases with ‘no
match <0.3’ (no calibrated score provided) were given
the value 0 to visualize them in this plot.
Fig S4. Effect of methylation profiling on final patholog-
ical diagnosis of specific subgroups. (A) Paediatric
(n=223); (B) Adult (n=279); (C) Subclassification
(n=43); (D) Challenging diagnosis (n=89).
Fig S5. Case 1. (A) FISH CMYC break-apart probe (red
and green signals) showing 4-6 signal pairs per
nucleus, indicative for polysomy; (B) FISH centromere
6 probe (yellow) showing 2-3 signals per nucleus, sug-
gesting relative loss of Chr 6; (C) SNP array suggesting
loss of chromosome 6; (D) SNP array adjusted for copy
number neutral loss of chromosome 6.
Data S1. Supplementary data.
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